Trials / Recruiting
RecruitingNCT06585449
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-HTT02 | ALN-HTT02 will be administered intrathecally |
| DRUG | Placebo | Placebo will be administered intrathecally |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2028-07-05
- Completion
- 2028-07-05
- First posted
- 2024-09-05
- Last updated
- 2026-03-31
Locations
19 sites across 3 countries: Canada, Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06585449. Inclusion in this directory is not an endorsement.